X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

HistoGenetics Selects PacBio(R) DNA Sequencing Platform to Enhance Human Leukocyte Antigen (HLA) Typing

Tuesday, April 29, 2014

MENLO PARK, Calif., April 29, 2014 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (Nasdaq:PACB) and HistoGenetics, a global leader in Human Leukocyte Antigen (HLA) sequence-based typing (SBT), announced today that HistoGenetics has selected the PacBio DNA Sequencing platform for its unique ability to sequence full-length HLA genes and to provide fully phased HLA alleles. HistoGenetics has purchased two PacBio RS II DNA Sequencing systems, which will be used for HLA typing and will be evaluated as potential replacements for Sanger sequencing.

Comprehensive characterization of an individual’s HLA type is important for research in tissue transplantation matching, autoimmune disease-association studies, drug hypersensitivity research, and other applications. The HLA genes are highly polymorphic, containing thousands of alleles that code for proteins that are important for recognizing foreign antigens. Accurate phasing of HLA polymorphisms using Sanger and short-read sequencing technologies has previously required confirmation, incurring additional expense. These methods also suffer from ambiguous calls when imputation data is required. The long read lengths (tens of thousands of bases) provided by PacBio sequencing are ideally suited for accurate allele-level genotyping since unambiguous allele phasing is critical for high-resolution allele assignment.

“As a leader in the HLA typing market, we aggressively seek out technologies that can accurately analyze this complex region of the genome. With its industry-leading read lengths, accuracy, and fast turnaround time, PacBio’s sequencing platform is exactly what this market needs,” said Dr. Nezih Cereb, Chief Executive Officer and co-founder of HistoGenetics. “We are eager to use our new PacBio RS II machines to get comprehensive, novel views of the HLA region and other genes relevant to immunology, such as KIR.”

Michael Hunkapiller, President and CEO of Pacific Biosciences commented: “The PacBio RS II system is the only commercial sequencer that can work through highly complex regions of the genome, and customers routinely tell us that it enables them to see genetic elements they have never been able to see before. As HistoGenetics applies this technology for HLA typing research, we believe they too will find novel insights that will be immensely useful to the biomedical research community.”

About HistoGenetics

HistoGenetics (www.histogenetics.com) is the global leader in HLA sequence-based typing (SBT). As a pioneer the field, the company has provided its services for donor registries, donor centers, cord blood banks, transplant centers, HLA laboratories and pharmacogenomics applications. To date, HistoGenetics has performed more than 14 million SBTs and discovered 19,000 samples carrying new alleles. The company was founded by Dr. Soo Young Yang, who serves as Chairman, and Dr. Nezih Cereb, Chief Executive Officer.

About the PacBio RS II and SMRT® Sequencing

Pacific Biosciences’ Single Molecule, Real-Time (SMRT) Sequencing technology achieves the industry’s longest read lengths, highest consensus accuracy i, iiand the least degree of bias.iii These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural and industrial problems.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

i Koren et al., “Reducing assembly complexity of microbial genomes with single-molecule sequencing.” Genome Biology, 14:R10.1 (2013).

ii Chin et al., “Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data.” Nature Methods, 10; 563-569 (2013).

iii Ross et al. Characterizing and measuring bias in sequence data. Genome Biol 14: R51 (2013).

CONTACT: Media:

         Nicole Litchfield

         For Pacific Biosciences

         415.793.6468

         nicole@bioscribe.com



         Investors:

         Trevin Rard

         Pacific Biosciences

         650.521.8450

         ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media

Press Release

Pacific Biosciences Announces New Chief Financial Officer

Monday, September 14, 2020

Stay
Current

Visit our blog »